Cargando…

CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders

Astrocytic impairment is a pathologic feature of neuromyelitis optica spectrum disorder (NMOSD). S100B and glial fibrillary acidic protein (GFAP) are the two most commonly used astrocytic markers. The aim of this study was to evaluate whether CSF-S100B could serve as a marker of NMOSD. We enrolled 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yuzhen, Chang, Haoxiao, Li, Xindi, Du, Li, Xu, Wangshu, Cong, Hengri, Yao, Yajun, Zhang, Xinghu, Yin, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217894/
https://www.ncbi.nlm.nih.gov/pubmed/30426010
http://dx.doi.org/10.1155/2018/5381239
_version_ 1783368370604736512
author Wei, Yuzhen
Chang, Haoxiao
Li, Xindi
Du, Li
Xu, Wangshu
Cong, Hengri
Yao, Yajun
Zhang, Xinghu
Yin, Linlin
author_facet Wei, Yuzhen
Chang, Haoxiao
Li, Xindi
Du, Li
Xu, Wangshu
Cong, Hengri
Yao, Yajun
Zhang, Xinghu
Yin, Linlin
author_sort Wei, Yuzhen
collection PubMed
description Astrocytic impairment is a pathologic feature of neuromyelitis optica spectrum disorder (NMOSD). S100B and glial fibrillary acidic protein (GFAP) are the two most commonly used astrocytic markers. The aim of this study was to evaluate whether CSF-S100B could serve as a marker of NMOSD. We enrolled 49 NMOSD patients [25 aquaporin-4 antibody (AQP4-Ab)–positive, 8 myelin-oligodendrocyte glycoprotein antibody (MOG-Ab)-positive, and 16 seronegative patients], 12 multiple sclerosis (MS) patients, and 15 other noninflammatory neurological diseases (OND) patients. The CSF levels of S100B and GFAP were measured by ELISA. Both CSF-S100B and GFAP levels significantly discriminated NMOSD from MS [area under curve (AUC) = 0.839 and 0.850, respectively] and OND (AUC = 0.839 and 0.850, respectively). The CSF-S100B levels differentiated AQP4-Ab–positive NMOSD from MOG-Ab–positive NMOSD with higher accuracy than the CSF-GFAP levels (AUC=0.865 and 0.772, respectively). The CSF-S100B levels also significantly discriminated MOG-Ab–positive patients from seronegative patients (AUC = 0.848). Both CSF-S100B and GFAP levels were correlated with the Expanded Disability Status Scale (EDSS) during remission. Only the CSF-S100B levels were correlated with the CSF WBC count and the EDSS during attack. The levels of CSF-S100B seemed to have a longer lasting time than the levels of CSF-GFAP, which may benefit patients who present late. As a result, CSF-S100B might be a potential candidate biomarker for NMOSD in discriminating, evaluating severity, and predicting disability.
format Online
Article
Text
id pubmed-6217894
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-62178942018-11-13 CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders Wei, Yuzhen Chang, Haoxiao Li, Xindi Du, Li Xu, Wangshu Cong, Hengri Yao, Yajun Zhang, Xinghu Yin, Linlin Biomed Res Int Research Article Astrocytic impairment is a pathologic feature of neuromyelitis optica spectrum disorder (NMOSD). S100B and glial fibrillary acidic protein (GFAP) are the two most commonly used astrocytic markers. The aim of this study was to evaluate whether CSF-S100B could serve as a marker of NMOSD. We enrolled 49 NMOSD patients [25 aquaporin-4 antibody (AQP4-Ab)–positive, 8 myelin-oligodendrocyte glycoprotein antibody (MOG-Ab)-positive, and 16 seronegative patients], 12 multiple sclerosis (MS) patients, and 15 other noninflammatory neurological diseases (OND) patients. The CSF levels of S100B and GFAP were measured by ELISA. Both CSF-S100B and GFAP levels significantly discriminated NMOSD from MS [area under curve (AUC) = 0.839 and 0.850, respectively] and OND (AUC = 0.839 and 0.850, respectively). The CSF-S100B levels differentiated AQP4-Ab–positive NMOSD from MOG-Ab–positive NMOSD with higher accuracy than the CSF-GFAP levels (AUC=0.865 and 0.772, respectively). The CSF-S100B levels also significantly discriminated MOG-Ab–positive patients from seronegative patients (AUC = 0.848). Both CSF-S100B and GFAP levels were correlated with the Expanded Disability Status Scale (EDSS) during remission. Only the CSF-S100B levels were correlated with the CSF WBC count and the EDSS during attack. The levels of CSF-S100B seemed to have a longer lasting time than the levels of CSF-GFAP, which may benefit patients who present late. As a result, CSF-S100B might be a potential candidate biomarker for NMOSD in discriminating, evaluating severity, and predicting disability. Hindawi 2018-10-22 /pmc/articles/PMC6217894/ /pubmed/30426010 http://dx.doi.org/10.1155/2018/5381239 Text en Copyright © 2018 Yuzhen Wei et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wei, Yuzhen
Chang, Haoxiao
Li, Xindi
Du, Li
Xu, Wangshu
Cong, Hengri
Yao, Yajun
Zhang, Xinghu
Yin, Linlin
CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
title CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
title_full CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
title_fullStr CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
title_full_unstemmed CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
title_short CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
title_sort csf-s100b is a potential candidate biomarker for neuromyelitis optica spectrum disorders
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217894/
https://www.ncbi.nlm.nih.gov/pubmed/30426010
http://dx.doi.org/10.1155/2018/5381239
work_keys_str_mv AT weiyuzhen csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders
AT changhaoxiao csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders
AT lixindi csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders
AT duli csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders
AT xuwangshu csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders
AT conghengri csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders
AT yaoyajun csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders
AT zhangxinghu csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders
AT yinlinlin csfs100bisapotentialcandidatebiomarkerforneuromyelitisopticaspectrumdisorders